nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.0126	0.114	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—CYP3A4—bone cancer	0.00807	0.0731	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—RGS1—bone cancer	0.008	0.0725	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—GRM4—bone cancer	0.008	0.0725	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—CYP3A4—bone cancer	0.0066	0.0598	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00541	0.049	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GRM4—bone cancer	0.00484	0.0439	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GRM1—bone cancer	0.0042	0.0381	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00416	0.0377	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SMO—bone cancer	0.00296	0.0268	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRM4—bone cancer	0.00274	0.0248	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—RGS1—bone cancer	0.00274	0.0248	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRM4—bone cancer	0.00249	0.0225	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RGS1—bone cancer	0.00249	0.0225	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRM1—bone cancer	0.00237	0.0215	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRM1—bone cancer	0.00216	0.0195	CbGpPWpGaD
Raltegravir—Decreased appetite—Cisplatin—bone cancer	0.00173	0.00194	CcSEcCtD
Raltegravir—Bronchitis—Epirubicin—bone cancer	0.00173	0.00194	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—bone cancer	0.00172	0.00193	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Cisplatin—bone cancer	0.00172	0.00193	CcSEcCtD
Raltegravir—Infestation NOS—Methotrexate—bone cancer	0.00171	0.00192	CcSEcCtD
Raltegravir—Infestation—Methotrexate—bone cancer	0.00171	0.00192	CcSEcCtD
Raltegravir—Depression—Methotrexate—bone cancer	0.00171	0.00192	CcSEcCtD
Raltegravir—Gastritis—Doxorubicin—bone cancer	0.0017	0.00191	CcSEcCtD
Raltegravir—Pain—Cisplatin—bone cancer	0.0017	0.00191	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.0017	0.00191	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.0017	0.00191	CcSEcCtD
Raltegravir—Renal failure—Methotrexate—bone cancer	0.00168	0.00189	CcSEcCtD
Raltegravir—Neutropenia—Epirubicin—bone cancer	0.00168	0.00189	CcSEcCtD
Raltegravir—Abdominal distension—Doxorubicin—bone cancer	0.00167	0.00188	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Epirubicin—bone cancer	0.00167	0.00188	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—bone cancer	0.00166	0.00187	CcSEcCtD
Raltegravir—Eosinophilia—Doxorubicin—bone cancer	0.00164	0.00185	CcSEcCtD
Raltegravir—Feeling abnormal—Cisplatin—bone cancer	0.00164	0.00184	CcSEcCtD
Raltegravir—Weight increased—Epirubicin—bone cancer	0.00163	0.00184	CcSEcCtD
Raltegravir—Haematuria—Methotrexate—bone cancer	0.00163	0.00183	CcSEcCtD
Raltegravir—Weight decreased—Epirubicin—bone cancer	0.00162	0.00183	CcSEcCtD
Raltegravir—Hyperglycaemia—Epirubicin—bone cancer	0.00162	0.00182	CcSEcCtD
Raltegravir—Hepatobiliary disease—Methotrexate—bone cancer	0.00162	0.00182	CcSEcCtD
Raltegravir—Epistaxis—Methotrexate—bone cancer	0.00161	0.00181	CcSEcCtD
Raltegravir—Infestation—Epirubicin—bone cancer	0.0016	0.0018	CcSEcCtD
Raltegravir—Infestation NOS—Epirubicin—bone cancer	0.0016	0.0018	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—bone cancer	0.0016	0.0018	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00159	0.00178	CcSEcCtD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—bone cancer	0.00159	0.0144	CbGpPWpGaD
Raltegravir—Renal failure—Epirubicin—bone cancer	0.00157	0.00177	CcSEcCtD
Raltegravir—Body temperature increased—Cisplatin—bone cancer	0.00157	0.00177	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—bone cancer	0.00157	0.00176	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—bone cancer	0.00155	0.00175	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00154	0.00174	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—bone cancer	0.00154	0.00173	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GNA11—bone cancer	0.00153	0.0139	CbGpPWpGaD
Raltegravir—Haematuria—Epirubicin—bone cancer	0.00153	0.00172	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—SMO—bone cancer	0.00152	0.0138	CbGpPWpGaD
Raltegravir—Urinary tract disorder—Methotrexate—bone cancer	0.00152	0.0017	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—bone cancer	0.00151	0.0017	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—bone cancer	0.00151	0.0017	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—bone cancer	0.00151	0.0017	CcSEcCtD
Raltegravir—Urethral disorder—Methotrexate—bone cancer	0.00151	0.00169	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—bone cancer	0.0015	0.00169	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—bone cancer	0.0015	0.00168	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—bone cancer	0.00148	0.00166	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—bone cancer	0.00148	0.00166	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—bone cancer	0.00148	0.00166	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GRM4—bone cancer	0.00147	0.0133	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RGS1—bone cancer	0.00147	0.0133	CbGpPWpGaD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00147	0.00165	CcSEcCtD
Raltegravir—Hypersensitivity—Cisplatin—bone cancer	0.00146	0.00165	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—bone cancer	0.00146	0.00164	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—bone cancer	0.00145	0.00163	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—bone cancer	0.00145	0.00163	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—bone cancer	0.00144	0.00162	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—bone cancer	0.00143	0.00161	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—bone cancer	0.00143	0.00161	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—bone cancer	0.00143	0.00161	CcSEcCtD
Raltegravir—Asthenia—Cisplatin—bone cancer	0.00143	0.0016	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—bone cancer	0.00143	0.0016	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—bone cancer	0.00142	0.0016	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—bone cancer	0.00142	0.00159	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—bone cancer	0.00141	0.00159	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—bone cancer	0.00141	0.00159	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—bone cancer	0.00141	0.00158	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—bone cancer	0.0014	0.00157	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—bone cancer	0.0014	0.00157	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—bone cancer	0.00139	0.00157	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—GNA11—bone cancer	0.00139	0.0126	CbGpPWpGaD
Raltegravir—Immune system disorder—Methotrexate—bone cancer	0.00139	0.00156	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—IL3—bone cancer	0.00139	0.0126	CbGpPWpGaD
Raltegravir—Visual impairment—Epirubicin—bone cancer	0.00138	0.00156	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—bone cancer	0.00138	0.00156	CcSEcCtD
Raltegravir—Chills—Methotrexate—bone cancer	0.00138	0.00155	CcSEcCtD
Raltegravir—Diarrhoea—Cisplatin—bone cancer	0.00136	0.00153	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—bone cancer	0.00136	0.00153	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—bone cancer	0.00136	0.00153	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—bone cancer	0.00135	0.00151	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—bone cancer	0.00134	0.00151	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—bone cancer	0.00134	0.00151	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—bone cancer	0.00134	0.0015	CcSEcCtD
Raltegravir—Erythema—Methotrexate—bone cancer	0.00134	0.0015	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—bone cancer	0.00133	0.0015	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—bone cancer	0.00133	0.00149	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—bone cancer	0.00132	0.00149	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—bone cancer	0.00131	0.00148	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—bone cancer	0.00131	0.00147	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—bone cancer	0.00131	0.00147	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—bone cancer	0.00131	0.00147	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—bone cancer	0.0013	0.00147	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—bone cancer	0.0013	0.00147	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—bone cancer	0.0013	0.00146	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—bone cancer	0.0013	0.00146	CcSEcCtD
Raltegravir—Back pain—Methotrexate—bone cancer	0.00129	0.00145	CcSEcCtD
Raltegravir—Chills—Epirubicin—bone cancer	0.00129	0.00145	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—bone cancer	0.00128	0.00144	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GRM1—bone cancer	0.00127	0.0115	CbGpPWpGaD
Raltegravir—Alopecia—Epirubicin—bone cancer	0.00127	0.00143	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—bone cancer	0.00126	0.00142	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL3—bone cancer	0.00126	0.0114	CbGpPWpGaD
Raltegravir—Mental disorder—Epirubicin—bone cancer	0.00126	0.00142	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—bone cancer	0.00126	0.00141	CcSEcCtD
Raltegravir—Rash—Cisplatin—bone cancer	0.00125	0.00141	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—bone cancer	0.00125	0.00141	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—bone cancer	0.00125	0.00141	CcSEcCtD
Raltegravir—Erythema—Epirubicin—bone cancer	0.00125	0.00141	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00124	0.0113	CbGpPWpGaD
Raltegravir—Eye disorder—Doxorubicin—bone cancer	0.00124	0.0014	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—bone cancer	0.00124	0.00139	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—bone cancer	0.00124	0.00139	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—bone cancer	0.00124	0.00139	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—bone cancer	0.00123	0.00139	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—bone cancer	0.00123	0.00139	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—bone cancer	0.00122	0.00138	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—bone cancer	0.00121	0.00137	CcSEcCtD
Raltegravir—Back pain—Epirubicin—bone cancer	0.00121	0.00136	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—bone cancer	0.00121	0.00136	CcSEcCtD
Raltegravir—Malaise—Methotrexate—bone cancer	0.00121	0.00135	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—bone cancer	0.0012	0.00135	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—bone cancer	0.0012	0.00135	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—bone cancer	0.0012	0.00135	CcSEcCtD
Raltegravir—Chills—Doxorubicin—bone cancer	0.00119	0.00134	CcSEcCtD
Raltegravir—Nausea—Cisplatin—bone cancer	0.00118	0.00133	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—bone cancer	0.00117	0.00132	CcSEcCtD
Raltegravir—Cough—Methotrexate—bone cancer	0.00117	0.00131	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—bone cancer	0.00116	0.00131	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—bone cancer	0.00116	0.0013	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—bone cancer	0.00116	0.0013	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—bone cancer	0.00116	0.0013	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—bone cancer	0.00116	0.0013	CcSEcCtD
Raltegravir—Agitation—Epirubicin—bone cancer	0.00115	0.00129	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—bone cancer	0.00114	0.00128	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—bone cancer	0.00114	0.00128	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—bone cancer	0.00114	0.00128	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—bone cancer	0.00114	0.00128	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—bone cancer	0.00113	0.00127	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00113	0.00127	CcSEcCtD
Raltegravir—Malaise—Epirubicin—bone cancer	0.00113	0.00127	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—bone cancer	0.00112	0.00126	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—bone cancer	0.00112	0.00126	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—bone cancer	0.00112	0.00126	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—bone cancer	0.00112	0.00126	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—bone cancer	0.00111	0.00124	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—bone cancer	0.0011	0.00124	CcSEcCtD
Raltegravir—Cough—Epirubicin—bone cancer	0.00109	0.00123	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP3A4—bone cancer	0.00108	0.00982	CbGpPWpGaD
Raltegravir—Infection—Methotrexate—bone cancer	0.00108	0.00122	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—bone cancer	0.00108	0.00121	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—bone cancer	0.00107	0.00121	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—bone cancer	0.00107	0.0012	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—bone cancer	0.00107	0.0012	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.00107	0.00969	CbGpPWpGaD
Raltegravir—Thrombocytopenia—Methotrexate—bone cancer	0.00107	0.0012	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—bone cancer	0.00106	0.0012	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—bone cancer	0.00106	0.0012	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—bone cancer	0.00106	0.0012	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—bone cancer	0.00106	0.0012	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—bone cancer	0.00106	0.00119	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—bone cancer	0.00106	0.00119	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00106	0.00119	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.00106	0.00958	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.00106	0.00958	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Methotrexate—bone cancer	0.00105	0.00119	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—bone cancer	0.00105	0.00118	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—bone cancer	0.00104	0.00117	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—bone cancer	0.00104	0.00117	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—bone cancer	0.00104	0.00117	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—bone cancer	0.00103	0.00116	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—bone cancer	0.00102	0.00115	CcSEcCtD
Raltegravir—Infection—Epirubicin—bone cancer	0.00101	0.00114	CcSEcCtD
Raltegravir—Cough—Doxorubicin—bone cancer	0.00101	0.00114	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—bone cancer	0.001	0.00113	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—bone cancer	0.001	0.00112	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—bone cancer	0.000999	0.00112	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000994	0.00112	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—bone cancer	0.000992	0.00111	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—bone cancer	0.000987	0.00111	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—bone cancer	0.000987	0.00111	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—bone cancer	0.000985	0.00111	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—bone cancer	0.000985	0.00111	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—bone cancer	0.000985	0.00111	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—bone cancer	0.000982	0.0011	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—bone cancer	0.00098	0.0011	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000979	0.0011	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000978	0.00886	CbGpPWpGaD
Raltegravir—Discomfort—Doxorubicin—bone cancer	0.000974	0.00109	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—bone cancer	0.00097	0.00109	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—bone cancer	0.000964	0.00108	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—bone cancer	0.00096	0.00108	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—bone cancer	0.000952	0.00107	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—bone cancer	0.000948	0.00107	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—bone cancer	0.000942	0.00106	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—bone cancer	0.000941	0.00106	CcSEcCtD
Raltegravir—Infection—Doxorubicin—bone cancer	0.000938	0.00105	CcSEcCtD
Raltegravir—Pain—Methotrexate—bone cancer	0.000933	0.00105	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00093	0.00105	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.000927	0.0084	CbGpPWpGaD
Raltegravir—Nervous system disorder—Doxorubicin—bone cancer	0.000926	0.00104	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—bone cancer	0.000925	0.00104	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—bone cancer	0.000923	0.00104	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—bone cancer	0.000918	0.00103	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—bone cancer	0.000917	0.00103	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000915	0.00829	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Doxorubicin—bone cancer	0.000913	0.00103	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—bone cancer	0.000908	0.00102	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—bone cancer	0.000899	0.00101	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—bone cancer	0.000899	0.00101	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SMO—bone cancer	0.000897	0.00813	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Methotrexate—bone cancer	0.000892	0.001	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—bone cancer	0.000887	0.000998	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—bone cancer	0.000881	0.000991	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—bone cancer	0.00088	0.000989	CcSEcCtD
Raltegravir—Constipation—Epirubicin—bone cancer	0.000873	0.000981	CcSEcCtD
Raltegravir—Pain—Epirubicin—bone cancer	0.000873	0.000981	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—bone cancer	0.000867	0.000974	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—bone cancer	0.000862	0.000969	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—bone cancer	0.000862	0.000969	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000861	0.000967	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—bone cancer	0.000854	0.00096	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—bone cancer	0.000848	0.000953	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—bone cancer	0.000841	0.000946	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—bone cancer	0.00084	0.000944	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—bone cancer	0.000835	0.000938	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—bone cancer	0.000832	0.000935	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—bone cancer	0.000821	0.000923	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GNA11—bone cancer	0.00082	0.00743	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000816	0.000917	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—bone cancer	0.000814	0.000915	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—bone cancer	0.000811	0.000912	CcSEcCtD
Raltegravir—Pain—Doxorubicin—bone cancer	0.000808	0.000908	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—bone cancer	0.000808	0.000908	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—bone cancer	0.000807	0.000907	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—bone cancer	0.000807	0.000907	CcSEcCtD
Raltegravir—Hypersensitivity—Methotrexate—bone cancer	0.000804	0.000903	CcSEcCtD
Raltegravir—Asthenia—Methotrexate—bone cancer	0.000783	0.00088	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—bone cancer	0.000778	0.000875	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—bone cancer	0.000772	0.000868	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—bone cancer	0.000772	0.000868	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ATF1—bone cancer	0.000763	0.00691	CbGpPWpGaD
Raltegravir—Hypersensitivity—Epirubicin—bone cancer	0.000752	0.000846	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—bone cancer	0.00075	0.000844	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—bone cancer	0.000747	0.000839	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—bone cancer	0.000747	0.000839	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—bone cancer	0.000746	0.000839	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL3—bone cancer	0.000744	0.00674	CbGpPWpGaD
Raltegravir—Asthenia—Epirubicin—bone cancer	0.000732	0.000823	CcSEcCtD
Raltegravir—Pruritus—Epirubicin—bone cancer	0.000722	0.000812	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—bone cancer	0.000721	0.000811	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—bone cancer	0.000699	0.000785	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—bone cancer	0.000696	0.000782	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—bone cancer	0.000694	0.00078	CcSEcCtD
Raltegravir—Rash—Methotrexate—bone cancer	0.000688	0.000773	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—bone cancer	0.000687	0.000772	CcSEcCtD
Raltegravir—Headache—Methotrexate—bone cancer	0.000683	0.000768	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—bone cancer	0.000678	0.000762	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—bone cancer	0.000675	0.000759	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—bone cancer	0.000668	0.000751	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NDUFA12—bone cancer	0.00065	0.00589	CbGpPWpGaD
Raltegravir—Vomiting—Epirubicin—bone cancer	0.000649	0.00073	CcSEcCtD
Raltegravir—Nausea—Methotrexate—bone cancer	0.000648	0.000728	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—bone cancer	0.000646	0.000727	CcSEcCtD
Raltegravir—Rash—Epirubicin—bone cancer	0.000644	0.000724	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—bone cancer	0.000643	0.000723	CcSEcCtD
Raltegravir—Headache—Epirubicin—bone cancer	0.00064	0.000719	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TGFBR2—bone cancer	0.000636	0.00576	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—bone cancer	0.000625	0.000702	CcSEcCtD
Raltegravir—Nausea—Epirubicin—bone cancer	0.000606	0.000682	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—bone cancer	0.000601	0.000675	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IGF1R—bone cancer	0.000599	0.00542	CbGpPWpGaD
Raltegravir—Rash—Doxorubicin—bone cancer	0.000596	0.00067	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—bone cancer	0.000595	0.000669	CcSEcCtD
Raltegravir—Headache—Doxorubicin—bone cancer	0.000592	0.000665	CcSEcCtD
Raltegravir—Nausea—Doxorubicin—bone cancer	0.000561	0.000631	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NT5C3A—bone cancer	0.000539	0.00488	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KIT—bone cancer	0.000434	0.00393	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—bone cancer	0.000408	0.0037	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—bone cancer	0.000395	0.00358	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MDM2—bone cancer	0.000342	0.0031	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUN—bone cancer	0.000297	0.00269	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP9—bone cancer	0.000289	0.00262	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ENO2—bone cancer	0.000236	0.00214	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGFR—bone cancer	0.000234	0.00212	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—DHFR—bone cancer	0.000219	0.00198	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNA11—bone cancer	0.000205	0.00185	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—bone cancer	0.000196	0.00178	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP3A4—bone cancer	0.000185	0.00168	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—bone cancer	0.000159	0.00144	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—bone cancer	8.22e-05	0.000744	CbGpPWpGaD
